Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, according to a new analysis. Separately, a group of state attorneys general has raised concerns about the ...
Sanofi’s hopes of getting its ... type 1 diabetes in the US have been dashed by the FDA. The US regulator has issued a complete response letter (CRL) for Lexicon Pharma-partnered sotagliflozin ...
The US Food and Drug Administration (FDA) has issued several warning letters to pharmaceutical manufacturers in India and China, citing serious violations of current good manufacturing practice (CGMP) ...
Sanofi bought back a $3.1 billion stake held by cosmetics giant L’Oréal. Journavx, a non-opioid pain medication made by Vertex Pharmaceuticals, received approval for adults from the FDA. United ...
Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...
As part of its enforcement activities, the Food and Drug Administration sends warning letters to entities under its jurisdiction. Some letters are not posted for public view until weeks or months ...
Some workers at the Environmental Protection Agency (EPA) have received a letter from the agency warning them that they may face termination amid the Trump administration's efforts to scale back ...
DZ Bank upgraded Sanofi (SNY) to Buy from Hold with a EUR 122 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See ...
Plus, the drug still has plenty of room left to grow in places like the U.S., Sanofi executives said on an analyst call Thursday. All told, Beyfortus generated 1.7 billion euros (about $1.8 ...
Sanofi SAN-1.58%decrease; red down pointing triangle forecast stronger earnings growth this year and said it planned to launch a $5.2 billion share buyback. The French pharmaceutical company said ...
One of the removed drug candidates, SAR445611, is an anti-CX3CR1 nanobody that Sanofi was developing in an inflammatory indication. The second jettisoned molecule is SAR444200, a GPC3-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results